Empaglifozin and the Reduction of Risk of Death in a High Cardiovascular Risk Population

  • Italo Cordeiro Moreira Faculdade de Medicina do ABC Estácio - FMJ
  • Gabriel Pereira Bernardo Estacio- FMJ
  • D'ávila Suyane Belém de Lima Estácio - FMJ
  • Cecilia Brenda Rocha Carneiro Estácio- FMJ
  • Débora Laésia Saraiva Ribeiro Estacio-FMJ
  • Mariana Carleial Feijó de Sá Estácio-FMJ
  • Maria Jaionara de Macedo Estácio- FMJ
  • Priscila Passos Campelo Moreira Estácio- FMJ
  • Vanessa Lacerda Araújo Estácio-FMJ
  • José Nunes de Alencar Neto Dante Pazzanese Institute of Cardiology
  • Herbert Lima Mendes Estácio- FMJ
  • Sérgio de Araújo Estácio-FMJ
  • Hermes Melo Teixeira Batista Estácio-FMJ
DOI: http://dx.doi.org/10.3823/2000

Abstract

Diabetes Mellitus (DM) is a chronic cardio-metabolic disease and plays an important role on cardiovascular outcomes, most importantly when associated with an already established heart disease. Its effects in the body involve both metabolic and structural changes. To avoid such complications, in addition to the strategies already used and known, rises the Empaglifozin, a sodium glucose co-transporter inhibitor 2 (SGLT2). Its benefits and efficacy have been tried and tested in large-scale trials, with multidimensional cardiovascular effects that go beyond the adequate glycemic control. The EMPA-REG Outcome materialize such benefits, especially for people at high cardiovascular risk, when significantly reduced cardiovascular death and death from any cause in this population.
Published
Jul 5, 2016
How to Cite
CORDEIRO MOREIRA, Italo et al. Empaglifozin and the Reduction of Risk of Death in a High Cardiovascular Risk Population. International Archives of Medicine, [S.l.], v. 9, july 2016. ISSN 1755-7682. Available at: <http://imed.pub/ojs/index.php/iam/article/view/1690>. Date accessed: 27 apr. 2018. doi: http://dx.doi.org/10.3823/2000.
Citation Formats
Issue
Vol 9 (2016)
Section
Cardiology

Keywords

Diabetes Mellitus, Empagliflozin, Cardiovascular Disease,
Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access and Benefits of Publishing Open Access).